Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Impax Laboratories, a technology based specialty pharmaceutical company, through its generic drug division Global Pharmaceuticals, has announced that the FDA has granted final approval of its abbreviated new drug application for a generic version of Prilosec 40mg delayed-release capsules.
Subscribe to our email newsletter
AstraZeneca markets Prilosec for the treatment of duodenal/gastric ulcers and gastro-esophageal reflux disease.
The company’s versions of generic Prilosec (including previously approved and marketed 10mg and 20mg capsules) are one of 12 products covered under its strategic alliance entered into in June 2001 with a subsidiary of Teva Pharmaceutical Industries. Teva began marketing the 40mg product immediately.